Date: 2015-12-02
Type of information: Private placement
Company: Santhera Pharmaceuticals (Switzerland)
Investors:
Amount: CHF 54.8 million (€ 50.2 million)
Funding type: private placement
Planned used: The proceeds of this share placement will be mainly used for the ongoing preparations for regulatory filings and market launch in Duchenne muscular dystrophy (DMD) in the US and Europe, for recently announced new clinical trial in DMD patients using glucocorticoid steroids and for launch of Raxone® for the treatment of Leber\'s hereditary optic neuropathy (LHON) in Europe and the implementation of post-approval measures agreed with the European Medicines Agency (EMA).
Others: * On December 2, 2015, Santhera Pharmaceuticals successfully completed the placement of shares which was announced yesterday. Santhera sold 590,000 new shares via a significantly oversubscribed accelerated bookbuilding process and raised gross proceeds of CHF 54.8 million. The shares were sold at a price of CHF 93.0 per share, a discount of 4.5% to the volume-weighted average price of December 1, 2015. The new shares from the Company\'s authorized capital were sold by way of a private placement in Switzerland and abroad in accordance with applicable securities laws. Following this transaction, the number of issued shares increased by 590,000 shares to new 6,262,718 shares, representing a 10.40% increase of the Company\'s issued share capital. Trading of the new shares on the SIX Swiss Exchange is expected to commence on December 3, 2015 and the settlement of the new shares is expected to take place on December 4, 2015. * On December 1, 2015, Santhera Pharmaceuticals announced that it plans to place up to 500,000 new shares from its authorized capital, representing 8.8% of the Company\'s currently outstanding shares. The new shares with a par value of CHF 1.00 per share will be issued from the Company\'s authorized capital on a non-preemptive basis. New shares are planned to be placed through an accelerated bookbuilding procedure by way of a private placement in Switzerland and abroad in accordance with applicable securities laws. In line with the articles of incorporation, the Board of Directors has excluded the preemptive rights of the existing shareholders. Santhera has also granted the bookrunners an option to place up to 100,000 additional shares, increasing the potential offer size to up to 600,000 shares. The shares underlying the increase option will also be sourced from the authorized capital. The price of the placed shares will be determined after the close of the bookbuilding period which is expected to end on December 2, 2015. Trading of the new shares on the SIX Swiss Exchange will commence on or around December 3, 2015. The new shares will be fully fungible and rank pari passu with the Company\'s existing shares.
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
